Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis

  • Corral Nieto, Yaiza
  • Fernández Pereira, Amanda Gabrielly
  • Ventura-San Pedro, Laura
  • Paredes, Sonia Belén
  • Pérez-Cobas, Ana Elena
  • Perez-Lanzon, María
  • Durand, Sylvere
  • Moreno-Cruz, Paula
  • Manrique, Laura
  • Benítez-Fernández, Rocío
  • Leal Lassalle, Héctor
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Alechaga, Élida
  • Pozo, Oscar J.
  • Boya, Patricia
  • Fuentes, José Manuel
  • Sica, Valentina
  • Kroemer, Guido
  • Bravo-San Pedro, José Manuel
Ciliopathies are genetic disorders characterized by defective primary cilia function, with obesity as a clinical manifestation in certain cases, including Alström syndrome, which is caused by ALMS1 mutations. The link between cilia and lipid metabolism remains poorly understood, but evidence suggests a role for impaired autophagy. Autophagy affects both intra- and extracellular levels of ACBP, which can act as an obesogenic factor. Our multi-omics study reveals early hepatic dyslipidemia, impaired autophagy, and hepatic accumulation of ACBP in presymptomatic male mice lacking Alms1 gene. These conditions are consistent with the obesogenic phenotype and with alterations in the gut microbiota that manifest as the mice age and develop obesity. Importantly, reducing excessive ACBP with a neutralizing monoclonal antibody limits weight gain and metabolic defects in Alms1-/- mice in an autophagy-independent manner. Altogether, the data support the idea that ciliopathy-associated obesity, particularly Alström syndrome, may be mitigated by ACBP neutralization., J.M.B.-S.P. was funded by MICIU/AEI/10.13039/501100011033 and by ESF Investing in your future (Ramón y Cajal Program, RYC-2018-025099-I). This work has been supported by the following grants: PID2019-108827RA-I00 funded by MICIU/AEI/10.13039/501100011033; PDC2022-133398-I00 funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. JMF was funded by the Instituto de Salud Carlos III, CIBERNED, grant number CB06/05/0041. YCN was funded by the Community of Madrid (CT5/21/PEJ-2020-TL/BMD-17685) and PDC2022-133398-I00 contract. AGFP was supported by RYC-2018-025099-I contract. AEP-C is funded by a Grant for the Attraction of Talent within the Community of Madrid (2019-T2/BMD-12874). L.V.-S.P. is funded by Barcelona Supercomputing Center (BSC). P.M.-C. was funded by the MINECO Spanish Ministry (FPI grant, PRE2020-092668). L.M. was funded by the INVESTIGO program (CAM, 09-PIN1-00009.8/2022). The authors thank Drs. Victoria Cachofeiro and Ernesto Martinez-Martinez for the support in the conceptualization and execution of this work; UCM animal facility for the daily care and control of the mice used in this study, especially to Susana and María Pilar Bringas de la Lastra; to Ana Romero Miranda, Beatriz Delgado García and Raquel Rodrigues Diez for helpful assistance with tissue evaluation; to Erwan Boëdec as responsible technique of plateforme Biochimie et Biophysique, Institut de Psychiatrie et Neurosciences de Paris (IPNP)/UMR_S1266 for the production of recombinant ACBP protein; to Dr. Laura Clavaín and EGO GENOMICS S.L. for the metabolomic statistical analysis; to the Facility of Innovation and Analysis in Animal Source Foodstuffs (SiPA) of SAIUEx of the University of Extremadura for carrying out proteomic analysis; and Dreamgenics for performing the experiments and bioinformatic analysis of RNAseq data. We thank the Translational Genomics Unit (NGS) of the Ramón y Cajal Institute for Health Research (IRYCIS) for performing the microbiota sequencing and preliminary analysis. We also thank Dr. Christopher C. Goodnow for kindly providing the Alms1-/- mouse model.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis

  • Corral Nieto, Yaiza
  • Fernández Pereira, Amanda Gabrielly
  • Ventura-San Pedro, Laura
  • Paredes, Sonia Belén
  • Pérez-Cobas, Ana Elena
  • Perez-Lanzon, María
  • Durand, Sylvere
  • Moreno-Cruz, Paula
  • Manrique, Laura
  • Benítez-Fernández, Rocío
  • Leal Lassalle, Héctor
  • Nevzorova, Yulia A.
  • Cubero, Francisco Javier
  • Alechaga, Élida
  • Pozo, Oscar J.
  • Boya, Patricia
  • Fuentes, José Manuel
  • Sica, Valentina
  • Kroemer, Guido
  • Bravo-San Pedro, José Manuel
Ciliopathies are genetic disorders characterized by defective primary cilia function, with obesity as a clinical manifestation in certain cases, including Alström syndrome, which is caused by ALMS1 mutations. The link between cilia and lipid metabolism remains poorly understood, but evidence suggests a role for impaired autophagy. Autophagy affects both intra- and extracellular levels of ACBP, which can act as an obesogenic factor. Our multi-omics study reveals early hepatic dyslipidemia, impaired autophagy, and hepatic accumulation of ACBP in presymptomatic male mice lacking Alms1 gene. These conditions are consistent with the obesogenic phenotype and with alterations in the gut microbiota that manifest as the mice age and develop obesity. Importantly, reducing excessive ACBP with a neutralizing monoclonal antibody limits weight gain and metabolic defects in Alms1-/- mice in an autophagy-independent manner. Altogether, the data support the idea that ciliopathy-associated obesity, particularly Alström syndrome, may be mitigated by ACBP neutralization., J.M.B.-S.P. was funded by MICIU/AEI/10.13039/501100011033 and by ESF Investing in your future (Ramón y Cajal Program, RYC-2018-025099-I). This work has been supported by the following grants: PID2019-108827RA-I00 funded by MICIU/AEI/10.13039/501100011033; PDC2022-133398-I00 funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. JMF was funded by the Instituto de Salud Carlos III, CIBERNED, grant number CB06/05/0041. YCN was funded by the Community of Madrid (CT5/21/PEJ-2020-TL/BMD-17685) and PDC2022-133398-I00 contract. AGFP was supported by RYC-2018-025099-I contract. AEP-C is funded by a Grant for the Attraction of Talent within the Community of Madrid (2019-T2/BMD-12874). L.V.-S.P. is funded by Barcelona Supercomputing Center (BSC). P.M.-C. was funded by the MINECO Spanish Ministry (FPI grant, PRE2020-092668). L.M. was funded by the INVESTIGO program (CAM, 09-PIN1-00009.8/2022). The authors thank Drs. Victoria Cachofeiro and Ernesto Martinez-Martinez for the support in the conceptualization and execution of this work; UCM animal facility for the daily care and control of the mice used in this study, especially to Susana and María Pilar Bringas de la Lastra; to Ana Romero Miranda, Beatriz Delgado García and Raquel Rodrigues Diez for helpful assistance with tissue evaluation; to Erwan Boëdec as responsible technique of plateforme Biochimie et Biophysique, Institut de Psychiatrie et Neurosciences de Paris (IPNP)/UMR_S1266 for the production of recombinant ACBP protein; to Dr. Laura Clavaín and EGO GENOMICS S.L. for the metabolomic statistical analysis; to the Facility of Innovation and Analysis in Animal Source Foodstuffs (SiPA) of SAIUEx of the University of Extremadura for carrying out proteomic analysis; and Dreamgenics for performing the experiments and bioinformatic analysis of RNAseq data. We thank the Translational Genomics Unit (NGS) of the Ramón y Cajal Institute for Health Research (IRYCIS) for performing the microbiota sequencing and preliminary analysis. We also thank Dr. Christopher C. Goodnow for kindly providing the Alms1-/- mouse model.